AustraliaBreaking News

Panmure Liberum economist Simon French discusses the UK economy and the political crisis surrounding Prime Minister Keir Starmer. Gross domestic product grew 0.6% in the first quarter, a jump from the 0.2% in the previous three months and the fastest expansion for a year. French speaks on Bloomberg Television.

Anna Edwards, Guy Johnson, Tom Mackenzie and Mark Cudmore break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade."

Services Australia formalised a $1.9 million agreement with FirstWave Cloud Technology (ASX:FCT) for AI-powered compliance management software.

Chinese President Xi Jinping pressed US President Donald Trump on the issue of Taiwan and warned of a potential conflict if mismanaged. The two leaders met Thursday morning at the Great Hall of the People in Beijing following an elaborate welcome ceremony during the first visit to China by a sitting US president in nearly a decade. Bloomberg's Minmin Low reports from Beijing.

Argenica Therapeutics (ASX:AGN) has formed a Clinical Advisory Committee to lead its Phase 2b trial for the neuroprotective candidate, ARG-007.

Artificial intelligence chipmaker Cerebras raised $5.55 billion in its US initial public offering. The company priced its shares at $185 each, giving Cerebras a market value of about $40 billion, based on the shares offered and outstanding in its filings. Bloomberg's Neil Campling reports.

Mercury NZ (ASX:MCY) unveiled a landmark NZ$1 billion investment strategy aimed at scaling its geothermal platform.

Investors in Acrux (ASX:ACR) received a boost following the release of the 2026/27 federal budget on May 12.

Hydrix (ASX:HYD) has secured a binding contract with the NIOA Group to develop advanced counter-drone payload technology.

EV Resources (ASX:EVR) announced an operational breakthrough at its Tecomatlán processing plant.

Australian food and beverage giant SPC Global (ASX:SPG) announced a $100 million capital injection.

Nexalis Therapeutics (ASX:NX1) announced a clinical milestone following the final dosing of its Phase 1 study for IRX-616a.